1. J. H. Fleisch, L. E. Rinkema, C. A. Whitesitt and W. S. Marshall,Pharmacologic antagonism of leukotriene-mediated events. InLeukotrienes: Their biological significance. (Ed P. J. Piper), pp. 109–125, Raven Press, New York 1986.
2. J. H. Fleisch, L. E. Rinkema, K. D. Haisch, D. Swanson-Bean, T. Goodson, P. P. K. Ho and W. S. Marshall,LY 171883, 1-[2-Hydroxy-3-propyl-4-[4-(1H-tetrazol-5-yl) butoxy]phenyl]ethanone, an orally active leukotriene D 4 antagonist. J. Pharmacol. Exp. Ther.223, 148–157 (1985).
3. J. M. Van Rossum,Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch. Int. Pharmacodyn. Ther.143, 229–330 (1963).
4. R. F. Furchgott,The classification of adrenoceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory. InHandbook of Experimental Pharmacology. (Eds. O. Eichler, A. Farah, H. Herken and A. D. Welch) vol. 33, pp. 283–335, Springer, New York 1972.